---
title: "XDH and ITPA linked to prognosis and cisplatin response in NSCLC: integrated bioinformatics and la"
id: "pubmed-42972208"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42972208"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42972208/"
doi: "10.1007/s10142-026-02100-x"
published_at: "2026-11-03T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# XDH and ITPA linked to prognosis and cisplatin response in NSCLC: integrated bioinformatics and la
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42972208
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42972208/)
- **DOI:** [10.1007/s10142-026-02100-x](https://doi.org/10.1007%2Fs10142-026-02100-x)
- **Published At:** 2026-11-03T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Investigators analyzed transcriptomes from TCGA and GTEx to identify differentially expressed purine metabolism genes in **NSCLC** and to assess associations with overall survival. - The team used ssGSEA to profile immune infiltration and queried single-cell datasets to map candidate-gene expression across tumor cell types and microenvironmental compartments. - Computational models estimated stemness (mRNAsi) and drug sensitivity; authors reported an association between higher **XDH** expression and predicted higher cisplatin IC50. - Protein-level validation employed Western blot and immunohistochemistry (IHC) in an independent NSCLC cohort; both **XDH** and **ITPA** showed higher tumor protein expression. - Stable knockdown of **XDH** or **ITPA** in H1299 cells reduced proliferation, clonogenicity, migration, and invasion; key phenotypes were recapitulated in A549 cells. - Experimental cisplatin dose-response assays demonstrated that **XDH** knockdown lowered measured cisplatin IC50 in H1299 and A549 cells, indicating altered chemosensitivity. - Data indicated altered immune-infiltration patterns associated with higher **XDH** and **ITPA** expression; the messenger RNA–based stemness index related to the two genes in opposite directions. - The study combined clinical, computational, single-cell, and cellular experiments but did not report detailed molecular mechanisms or broader clinical applicability beyond the analyzed cohorts. - Authors noted adherence to ethical standards, with local ethics approval and patient consent recorded; conflicts of interest were declared absent.
## Clinical Analysis & Structured Key Points
Integrative bioinformatics and experimental validation of the prognostic and functional relevance of XDH and ITPA in non-small cell lung cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to Clipboard My Bibliography Collections Citation manager Display options Display options Format Abstract PubMed PMID Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel Email citation Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Please try again Add Cancel Your saved search Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons Yes No Email: ( change ) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy Actions Cite Collections Add to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID Experimental Resource Linked Discoveries Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries Abstract Purine metabolism has been implicated in tumor biology and immune regulation, but the clinical and biological relevance of purine metabolism-related genes in non-small cell lung cancer (NSCLC) remains incompletely defined. Transcriptomic data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project, together with TCGA clinical data, were analyzed to identify differentially expressed purine metabolism-related genes and assess their prognostic associations. Immune infiltration was evaluated using single-sample gene set enrichment analysis (ssGSEA), and single-cell transcriptomic datasets were analyzed to characterize the cellular context of candidate genes. Stemness features and drug sensitivity were assessed using transcriptome-based computational models. XDH and ITPA protein expression was examined by Western blotting and immunohistochemistry (IHC) in an independent NSCLC cohort and in cell models. Stable knockdown of XDH or ITPA was performed in H1299 cells, with key functional findings further evaluated in A549 cells. Cisplatin sensitivity was assessed using cell-viability dose-response assays in H1299 and A549 cells. Several purine metabolism-related genes were upregulated in NSCLC and associated with overall survival (OS). XDH and ITPA showed higher protein expression in tumor tissues and were associated with adverse clinicopathological features and poorer survival. Higher expression of these genes was also associated with altered immune infiltration patterns. The messenger RNA-based stemness index (mRNAsi) was associated with ITPA and XDH expression in different directions, whereas higher XDH expression was associated with higher predicted half-maximal inhibitory concentration (IC50) values for cisplatin. Knockdown of XDH or ITPA attenuated proliferative, clonogenic, migratory, and invasive phenotypes in H1299 cells, with key findings reproduced in A549 cells. XDH knockdown also reduced the experimentally determined cisplatin IC50 in both H1299 and A549 cells. XDH and ITPA may represent candidate prognostic and functionally relevant purine metabolism-related genes in NSCLC. The integrated clinical, computational, and cellular findings support their association with NSCLC progression-related phenotypes, while the underlying molecular mechanisms and broader clinical applicability require further investigation. Keywords: ITPA; NSCLC; Prognosis; Purine Metabolism; XDH. © 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. PubMed Disclaimer Conflict of interest statement Declarations. Ethics Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Yancheng Third People’s Hospital (Affiliated Hospital 6 of Nantong University) (No. 2025-78). Written informed consent was obtained from all patients. Conflict of interest: The authors have no conflict of interest. Competing interests: The authors declare no competing interests. Clinical Trial Number: Not applicable. References Bray F et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229–263 - PubMed Stine ZE, Schug ZT, Salvino JM, Dang CV (2022) Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov 21:141–162 - DOI - PubMed Hanahan D (2022) Hallmarks of Cancer: New Dimensions. Cancer Discov 12:31–46 - DOI - PubMed Mullen NJ, Singh PK (2023) Nucleotide metabolism: a pan-cancer metabolic dependency. Nat Rev Cancer 23:275–294 - DOI - PubMed - PMC Martínez-Reyes I, Chandel NS (2021) Cancer metabolism: looking forward. Nat Rev Cancer 21:669–680 - DOI - PubMed Show all 24 references MeSH terms Carcinoma, Non-Small-Cell Lung* / drug therapy Actions Search in PubMed Search in MeSH Add to Search Carcinoma, Non-Small-Cell Lung* / genetics Actions Search in PubMed Search in MeSH Add to Search Carcinoma, Non-Small-Cell Lung* / metabolism Actions Search in PubMed Search in MeSH Add to Search Carcinoma, Non-Small-Cell Lung* / pathology Actions Search in PubMed Search in MeSH Add to Search Cell Line, Tumor Actions Search in PubMed Search in MeSH Add to Search Cisplatin / pharmacology Actions Search in PubMed Search in MeSH Add to Search Computational Biology Actions Search in PubMed Search in MeSH Add to Search Female Actions Search in PubMed Search in MeSH Add to Search Gene Expression Regulation, Neoplastic Actions Search in PubMed Search in MeSH Add to Search Humans Actions Search in PubMed Search in MeSH Add to Search Lung Neoplasms* / genetics Actions Search in PubMed Search in MeSH Add to Search Lung Neoplasms* / metabolism Actions Search in PubMed Search in MeSH Add to Search Lung Neoplasms* / pathology Actions Search in PubMed Search in MeSH Add to Search Male Actions Search in PubMed Search in MeSH Add to Search Prognosis Actions Search in PubMed Search in MeSH Add to Search Substances Cisplatin Actions Search in PubMed Search in MeSH Add to Search Grants and funding LKZ2024018/2024 Jiangsu Provincial Health Commission Scientific Research Project on Elderly Health 2024JZ009/2024 Nantong University Clinical Medicine Special Fund YCBE202421/2024 Yancheng City Key R&D Program (Social Development) Directive Project YXY-Z2023008/Nantong University's 2023 Academic Level Research Project (Special Project of Yancheng. Third Institute) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM Send To Clipboard Email Save My Bibliography Collections Citation Manager [x] NCBI Literature Resources MeSH PMC Bookshelf Disclaimer The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
## Related Clinical Research

- [Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings](https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced.md)
- [Chromeno[8,7-d]oxazole Lead AT-11: A CDK16 Inhibitor with Improved Solubility and Antitumor Activi](https://medichelpline.com/clinical-feed/pubmed-42822357.md) (DOI: 10.1016/j.bioorg.2026.110559)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)
- [CLDN18.2 targeting increases chemotherapy sensitivity in pancreatic and lung cancer models](https://medichelpline.com/clinical-feed/pubmed-42772182.md) (DOI: 10.1016/j.bbrc.2026.154610)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.